[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-001", "question": "A 71-year-old woman with a dual-chamber pacemaker (DDDR) for sick sinus syndrome presents with episodic dizziness and syncope. Device interrogation reveals normal lead parameters but frequent pacemaker-mediated tachycardia (PMT) episodes terminated by the device's algorithm. However, she continues to report symptoms. Telemetry shows intermittent 2:1 AV block during atrial tracking, with every second P wave falling within post-ventricular atrial refractory period (PVARP). Which programming adjustment will most effectively eliminate symptoms while preserving maximal atrioventricular synchrony?", "options": ["Extend PVARP by 50 ms", "Enable dynamic PVARP extension after premature ventricular contractions", "Reduce upper tracking limit to 120 bpm", "Switch to DDI mode at rest", "Enable atrial preference pacing"], "answer": "B", "answer_index": 1, "explanation": "Dynamic PVARP extension after PVCs prevents retrograde conduction from initiating PMT while preserving atrial tracking during sinus rhythm. Extending PVARP statically (A) would worsen 2:1 block and cause pacemaker syndrome. Reducing upper tracking (C) does not prevent PMT initiation. DDI mode (D) eliminates atrial tracking entirely. Atrial preference pacing (E) is irrelevant to PMT prevention.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes PMT episodes that are already terminated by the device's algorithm, yet the patient remains symptomatic. The telemetry finding of 2:1 AV block during atrial tracking with P waves falling in PVARP suggests upper rate behavior, not PMT. This creates confusion about the primary problem: is it recurrent PMT initiation (favoring option B) or 2:1 block from excessive PVARP (favoring option A shortening, though extending PVARP per option A would worsen this)? Option B (dynamic PVARP after PVCs) prevents PMT re-initiation but doesn't address the described 2:1 block. Option C (reducing upper tracking limit) could prevent 2:1 block by lowering the rate at which PVARP causes functional block. The stem conflates two distinct pacemaker issues without clarifying which is causing ongoing symptoms. Medical accuracy issue: The rationale claims extending PVARP (A) would worsen 2:1 block and cause pacemaker syndrome, which is correct, but doesn't explain why reducing upper tracking (C) wouldn't address the 2:1 block problem described in telemetry. Minimal fix: Clarify whether ongoing symptoms are from recurrent PMT despite termination algorithms or from symptomatic 2:1 block, and ensure telemetry findings match the intended pathophysiology.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes PMT episodes that are already terminated by the device's algorithm, yet the patient remains symptomatic. The telemetry finding of 2:1 AV block during atrial tracking with P waves falling in PVARP suggests upper rate behavior, not PMT. This creates confusion about the primary problem: is it recurrent PMT initiation (favoring option B) or 2:1 block from excessive PVARP (favoring option A shortening, though extending PVARP per option A would worsen this)? Option B (dynamic PVARP after PVCs) prevents PMT re-initiation but doesn't address the described 2:1 block. Option C (reducing upper tracking limit) could prevent 2:1 block by lowering the rate at which PVARP causes functional block. The stem conflates two distinct pacemaker issues without clarifying which is causing ongoing symptoms. Medical accuracy issue: The rationale claims extending PVARP (A) would worsen 2:1 block and cause pacemaker syndrome, which is correct, but doesn't explain why reducing upper tracking (C) wouldn't address the 2:1 block problem described in telemetry. Minimal fix: Clarify whether ongoing symptoms are from recurrent PMT despite termination algorithms or from symptomatic 2:1 block, and ensure telemetry findings match the intended pathophysiology.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-002", "question": "A 42-year-old man with a heterozygous CSF1R p.Arg782His mutation and early-stage adult-onset leukoencephalopathy with axonal spheroids (ALSP) has mild cognitive impairment and gait instability. His sister progressed to severe dementia within 3 years of symptom onset. Which intervention has demonstrated the highest disease-modifying efficacy when performed before onset of severe motor disability?", "options": ["Intravenous immunoglobulin monthly", "Oral cyclophosphamide 2 mg/kg/day", "Allogeneic hematopoietic stem cell transplantation from HLA-matched sibling donor", "Ruxolitinib 20 mg twice daily", "Supportive care with donepezil"], "answer": "C", "answer_index": 2, "explanation": "Allogeneic HSCT is the only intervention shown to halt ALSP progression when performed early, before severe disability, by replacing microglial precursors. IVIG (A) and cyclophosphamide (B) lack efficacy. Ruxolitinib (D) has no clinical data. Supportive care (E) does not modify disease course. Delay until severe motor impairment predicts transplant failure.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The question asks for the intervention with highest disease-modifying efficacy in early-stage ALSP before severe motor disability. Key stem clues: heterozygous CSF1R mutation (confirms ALSP diagnosis), early-stage disease with mild cognitive impairment and gait instability, family history of rapid progression. ALSP is a rare microglial disorder caused by CSF1R mutations. Allogeneic HSCT (C) is the only intervention with published evidence of disease stabilization/modification in ALSP when performed early, as it replaces defective microglial precursors. The timing emphasis (before severe motor disability) is critical, as outcomes worsen with advanced disease. IVIG (A) and cyclophosphamide (B) lack evidence in ALSP. Ruxolitinib (D), a JAK inhibitor, has no established role. Donepezil (E) is symptomatic only. No other options are defensible as disease-modifying. Medical accuracy: The item reflects emerging literature on HSCT for ALSP, though data remain limited to case series/small cohorts rather than controlled trials. The pathophysiologic rationale (microglial replacement) is sound. The emphasis on early intervention timing aligns with reported outcomes. Minimal fix: None required; item is logically valid with a unique best answer matching the key, though acknowledging the limited evidence base would enhance transparency.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The question asks for the intervention with highest disease-modifying efficacy in early-stage ALSP before severe motor disability. Key stem clues: heterozygous CSF1R mutation (confirms ALSP diagnosis), early-stage disease with mild cognitive impairment and gait instability, family history of rapid progression. ALSP is a rare microglial disorder caused by CSF1R mutations. Allogeneic HSCT (C) is the only intervention with published evidence of disease stabilization/modification in ALSP when performed early, as it replaces defective microglial precursors. The timing emphasis (before severe motor disability) is critical, as outcomes worsen with advanced disease. IVIG (A) and cyclophosphamide (B) lack evidence in ALSP. Ruxolitinib (D), a JAK inhibitor, has no established role. Donepezil (E) is symptomatic only. No other options are defensible as disease-modifying. Medical accuracy: The item reflects emerging literature on HSCT for ALSP, though data remain limited to case series/small cohorts rather than controlled trials. The pathophysiologic rationale (microglial replacement) is sound. The emphasis on early intervention timing aligns with reported outcomes. Minimal fix: None required; item is logically valid with a unique best answer matching the key, though acknowledging the limited evidence base would enhance transparency.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-003", "question": "A 64-year-old man with metastatic hemangiopericytoma presents with refractory hypoglycemia (glucose 28 mg/dL) despite 20% dextrose infusion at 100 mL/hour. Labs show insulin <2 μIU/mL, C-peptide 0.1 ng/mL, IGF-2 850 ng/mL (normal 50-200), and IGF-2:IGF-1 ratio 12:1. Which immediate pharmacologic intervention is most likely to achieve euglycemia within 24 hours?", "options": ["Continuous hydrocortisone infusion 10 mg/hour", "Recombinant IGF-1 40 mg subcutaneously twice daily", "Diazoxide 300 mg orally three times daily", "Octreotide 200 μg subcutaneously three times daily", "Glucagon 2 mg intramuscularly every 4 hours"], "answer": "A", "answer_index": 0, "explanation": "High-dose glucocorticoids suppress aberrant IGF-2 production from the tumor, correcting hypoglycemia within hours. Recombinant IGF-1 (B) worsens the IGF-2:IGF-1 imbalance. Diazoxide (C) and octreotide (D) are ineffective in non-islet cell tumor hypoglycemia due to suppressed insulin. Glucagon (E) provides only transient effect and cannot sustain normoglycemia.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - glucocorticoids are NOT the most effective immediate intervention. The vignette describes non-islet cell tumor hypoglycemia (NICTH) from hemangiopericytoma producing big IGF-2, confirmed by suppressed insulin/C-peptide, elevated IGF-2 (850 ng/mL), and high IGF-2:IGF-1 ratio (12:1). Key discriminating findings: refractory hypoglycemia despite high-dose dextrose, tumor source, and biochemical profile. While glucocorticoids (A) can suppress IGF-2 production, they typically require days to weeks for effect, not 24 hours. Recombinant IGF-1 (B) is the established treatment for NICTH - it normalizes the IGF-2:IGF-1 ratio, restores IGF binding proteins, reduces free IGF-2, and works within hours to days. The rationale incorrectly states IGF-1 'worsens the imbalance' when it actually corrects the pathophysiology by competitive binding. Diazoxide (C) and octreotide (D) are correctly eliminated (insulin already suppressed). Glucagon (E) provides only transient effect. The item contains a medical accuracy error: glucocorticoids do not achieve euglycemia within 24 hours in NICTH; IGF-1 does. Minimal fix: Change key to B (recombinant IGF-1) or reframe question to ask about adjunctive therapy rather than immediate intervention.\", \"medical_accuracy_score\": \"2\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - glucocorticoids are NOT the most effective immediate intervention. The vignette describes non-islet cell tumor hypoglycemia (NICTH) from hemangiopericytoma producing big IGF-2, confirmed by suppressed insulin/C-peptide, elevated IGF-2 (850 ng/mL), and high IGF-2:IGF-1 ratio (12:1). Key discriminating findings: refractory hypoglycemia despite high-dose dextrose, tumor source, and biochemical profile. While glucocorticoids (A) can suppress IGF-2 production, they typically require days to weeks for effect, not 24 hours. Recombinant IGF-1 (B) is the established treatment for NICTH - it normalizes the IGF-2:IGF-1 ratio, restores IGF binding proteins, reduces free IGF-2, and works within hours to days. The rationale incorrectly states IGF-1 'worsens the imbalance' when it actually corrects the pathophysiology by competitive binding. Diazoxide (C) and octreotide (D) are correctly eliminated (insulin already suppressed). Glucagon (E) provides only transient effect. The item contains a medical accuracy error: glucocorticoids do not achieve euglycemia within 24 hours in NICTH; IGF-1 does. Minimal fix: Change key to B (recombinant IGF-1) or reframe question to ask about adjunctive therapy rather than immediate intervention.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-004", "question": "A 59-year-old woman with rheumatoid arthritis on methotrexate develops progressive dyspnea and weight loss. HRCT demonstrates upper lobe-predominant pleural thickening, subpleural consolidation, and traction bronchiectasis with severe volume loss. Surgical lung biopsy shows dense subpleural fibrosis with prominent elastic fiber deposition and minimal inflammation, extending into the pleura. Which histopathologic finding most strongly differentiates this from usual interstitial pneumonia?", "options": ["Fibroblast foci within alveolar walls", "Honeycomb change with mucin-filled cysts", "Presence of intra-alveolar fibroblastic plugs", "Elastosis involving visceral pleura and subpleural parenchyma", "Patchy temporally heterogeneous fibrosis"], "answer": "D", "answer_index": 3, "explanation": "Pleuroparenchymal fibroelastosis (PPFE) is defined by characteristic elastosis of both pleura and subpleural parenchyma, which is absent in UIP. Fibroblast foci (A) and honeycomb change (B) are hallmark UIP features. Intra-alveolar fibroblastic plugs (C) suggest organizing pneumonia. Patchy heterogeneous fibrosis (E) is typical of UIP, whereas PPFE shows uniform elastotic fibrosis.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. The vignette describes a patient with rheumatoid arthritis on methotrexate presenting with upper lobe-predominant pleural thickening, subpleural consolidation, traction bronchiectasis, and severe volume loss. The biopsy shows dense subpleural fibrosis with prominent elastic fiber deposition and minimal inflammation extending into pleura—classic features of pleuroparenchymal fibroelastosis (PPFE). The question asks what histopathologic finding most strongly differentiates this from usual interstitial pneumonia (UIP). Key discriminating findings: upper lobe predominance, pleural involvement, elastic fiber deposition (elastosis), minimal inflammation. Option D (elastosis involving visceral pleura and subpleural parenchyma) is the defining histologic feature of PPFE and is absent in UIP, making it the correct differentiating feature. Options A, B, and E describe typical UIP features that would not differentiate PPFE from UIP. Option C describes organizing pneumonia, not a UIP feature. The stem provides sufficient detail to identify PPFE and distinguish it from UIP. Medical accuracy is excellent—PPFE is correctly characterized with its pathognomonic elastosis. Minimal fix: None needed; item is logically valid and medically accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. The vignette describes a patient with rheumatoid arthritis on methotrexate presenting with upper lobe-predominant pleural thickening, subpleural consolidation, traction bronchiectasis, and severe volume loss. The biopsy shows dense subpleural fibrosis with prominent elastic fiber deposition and minimal inflammation extending into pleura—classic features of pleuroparenchymal fibroelastosis (PPFE). The question asks what histopathologic finding most strongly differentiates this from usual interstitial pneumonia (UIP). Key discriminating findings: upper lobe predominance, pleural involvement, elastic fiber deposition (elastosis), minimal inflammation. Option D (elastosis involving visceral pleura and subpleural parenchyma) is the defining histologic feature of PPFE and is absent in UIP, making it the correct differentiating feature. Options A, B, and E describe typical UIP features that would not differentiate PPFE from UIP. Option C describes organizing pneumonia, not a UIP feature. The stem provides sufficient detail to identify PPFE and distinguish it from UIP. Medical accuracy is excellent—PPFE is correctly characterized with its pathognomonic elastosis. Minimal fix: None needed; item is logically valid and medically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-005", "question": "A 26-year-old woman ingests 60 mg of colchicine in a suicide attempt, presenting 8 hours later with profuse vomiting and diarrhea. Labs: WBC 22,000/μL, platelets 600,000/μL. Which intervention, when initiated within 12 hours of ingestion, has demonstrated mortality reduction in severe colchicine poisoning?", "options": ["Colchicine-specific Fab fragments 4 g IV bolus", "Granulocyte colony-stimulating factor 5 μg/kg/day subcutaneously", "Continuous venovenous hemofiltration at 50 mL/kg/hour", "N-acetylcysteine 150 mg/kg IV loading dose", "Plasma exchange daily for 5 days"], "answer": "B", "answer_index": 1, "explanation": "Early G-CSF administration reduces mortality by preventing septic complications from bone marrow suppression that begins 24-48 hours post-ingestion. Colchicine Fab (A) is experimental and unavailable. CVVH (C) does not enhance colchicine clearance due to large volume of distribution. NAC (D) has no role. Plasma exchange (E) is ineffective for intracellular toxins.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed – the keyed answer (B, G-CSF) is not the best answer; supportive care is standard. The stem describes severe colchicine poisoning (60 mg ingestion, GI symptoms, leukocytosis, thrombocytosis at 8 hours). The question asks which intervention \\\"has demonstrated mortality reduction\\\" when initiated within 12 hours. Key issue: No intervention listed has robust evidence for mortality reduction in colchicine poisoning. Standard management is aggressive supportive care. G-CSF (option B) is sometimes used for neutropenia in late-stage colchicine toxicity (days 3-7), but evidence for mortality benefit is weak and anecdotal; it's not standard within 12 hours when bone marrow suppression hasn't yet occurred. The rationale incorrectly states G-CSF prevents septic complications from marrow suppression \\\"beginning 24-48 hours post-ingestion\\\" – but at 8 hours presentation, prophylactic G-CSF lacks evidence. Colchicine-Fab (A) has case reports suggesting benefit but remains experimental/unavailable in most settings. CVVH (C), NAC (D), and plasma exchange (E) lack evidence. Medical accuracy issues: The premise that any listed intervention has \\\"demonstrated\\\" mortality reduction is questionable; the item conflates theoretical rationale with proven efficacy. Minimal fix: Reframe to ask \\\"most appropriate supportive measure\\\" or acknowledge evidence limitations, or change key to \\\"none of the above.\\\"\", \"medical_accuracy_score\": \"2\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed – the keyed answer (B, G-CSF) is not the best answer; supportive care is standard. The stem describes severe colchicine poisoning (60 mg ingestion, GI symptoms, leukocytosis, thrombocytosis at 8 hours). The question asks which intervention \"has demonstrated mortality reduction\" when initiated within 12 hours. Key issue: No intervention listed has robust evidence for mortality reduction in colchicine poisoning. Standard management is aggressive supportive care. G-CSF (option B) is sometimes used for neutropenia in late-stage colchicine toxicity (days 3-7), but evidence for mortality benefit is weak and anecdotal; it's not standard within 12 hours when bone marrow suppression hasn't yet occurred. The rationale incorrectly states G-CSF prevents septic complications from marrow suppression \"beginning 24-48 hours post-ingestion\" – but at 8 hours presentation, prophylactic G-CSF lacks evidence. Colchicine-Fab (A) has case reports suggesting benefit but remains experimental/unavailable in most settings. CVVH (C), NAC (D), and plasma exchange (E) lack evidence. Medical accuracy issues: The premise that any listed intervention has \"demonstrated\" mortality reduction is questionable; the item conflates theoretical rationale with proven efficacy. Minimal fix: Reframe to ask \"most appropriate supportive measure\" or acknowledge evidence limitations, or change key to \"none of the above.\"", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-006", "question": "A 55-year-old man with severe Barlow's disease undergoes 3D transesophageal echocardiography for mitral valve repair planning. The surgeon asks you to identify the parameter that best predicts durable repair. Which measurement most strongly correlates with successful leaflet coaptation after annuloplasty?", "options": ["Anterior leaflet length >35 mm", "Posterior leaflet thickness >5 mm", "Annular height to commissural width ratio >0.3", "Flail gap distance <10 mm", "Coaptation depth >15 mm"], "answer": "C", "answer_index": 2, "explanation": "Annular height to commissural width ratio >0.3 indicates adequate leaflet tissue and annular dynamics, predicting successful repair. Excessive leaflet length (A) and thickness (B) increase complexity but do not predict success. Flail gap (D) and coaptation depth (E) are important but secondary to annular geometry in Barlow's disease where tissue redundancy is the primary pathology.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: U (Underspecified, leading to M). Verdict: Not uniquely determinable. The question asks which measurement \\\"most strongly correlates\\\" with successful repair in Barlow's disease (myxomatous mitral valve with excess tissue). Key stem clues: 55-year-old man, severe Barlow's disease, 3D TEE for repair planning. The keyed answer (C: annular height-to-commissural width ratio >0.3) is presented as predicting \\\"adequate leaflet tissue and annular dynamics.\\\" However, this parameter is not a standard, widely-cited predictor in Barlow's repair literature. Established predictors include coaptation depth/length, posterior leaflet angle, and flail gap. The rationale dismisses coaptation depth (E) as \\\"secondary,\\\" yet coaptation depth >10-11mm is a recognized risk factor for repair failure in degenerative disease. The item lacks citation of specific evidence that ratio >0.3 is superior to coaptation depth for predicting durability. Without this critical detail, multiple answers become defensible based on different literature interpretations. Main logical issue: The stem assumes a hierarchy of predictors not universally established, creating ambiguity between C and E. Main medical accuracy issue: The annular height-to-commissural width ratio is not a mainstream predictor in standard texts/guidelines for Barlow's repair success. Minimal fix: Specify \\\"according to [specific study/guideline]\\\" or replace with a universally recognized parameter like coaptation length.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified, leading to M). Verdict: Not uniquely determinable. The question asks which measurement \"most strongly correlates\" with successful repair in Barlow's disease (myxomatous mitral valve with excess tissue). Key stem clues: 55-year-old man, severe Barlow's disease, 3D TEE for repair planning. The keyed answer (C: annular height-to-commissural width ratio >0.3) is presented as predicting \"adequate leaflet tissue and annular dynamics.\" However, this parameter is not a standard, widely-cited predictor in Barlow's repair literature. Established predictors include coaptation depth/length, posterior leaflet angle, and flail gap. The rationale dismisses coaptation depth (E) as \"secondary,\" yet coaptation depth >10-11mm is a recognized risk factor for repair failure in degenerative disease. The item lacks citation of specific evidence that ratio >0.3 is superior to coaptation depth for predicting durability. Without this critical detail, multiple answers become defensible based on different literature interpretations. Main logical issue: The stem assumes a hierarchy of predictors not universally established, creating ambiguity between C and E. Main medical accuracy issue: The annular height-to-commissural width ratio is not a mainstream predictor in standard texts/guidelines for Barlow's repair success. Minimal fix: Specify \"according to [specific study/guideline]\" or replace with a universally recognized parameter like coaptation length.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-007", "question": "A 67-year-old man presents with 18 months of progressive insomnia, dysautonomia, bulbar dysfunction, and gait instability. Polysomnography shows severe sleep fragmentation with complete loss of REM sleep. Anti-IgLON5 antibodies are positive in serum and CSF. Which therapeutic strategy has demonstrated modest symptomatic benefit in this tauopathy-mediated autoimmune disorder?", "options": ["High-dose intravenous methylprednisolone 1 g daily for 5 days", "Plasma exchange every other day for 2 weeks", "Rituximab 1 g IV every 2 weeks for 2 doses", "Combined immunotherapy with steroids, IVIG, and rituximab", "Trazodone 100 mg nightly for sleep restoration"], "answer": "D", "answer_index": 3, "explanation": "Combined immunotherapy offers modest benefit in IgLON5 disease by targeting both autoimmune and inflammatory components, though tauopathy progression continues. Monotherapy with steroids (A), plasma exchange (B), or rituximab (C) alone has shown minimal efficacy. Trazodone (E) cannot restore lost REM sleep architecture in this neurodegenerative disorder.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes classic anti-IgLON5 disease: progressive insomnia, dysautonomia, bulbar dysfunction, gait instability, polysomnography showing REM sleep loss, and positive anti-IgLON5 antibodies. The question asks which therapeutic strategy has demonstrated modest symptomatic benefit. Key discriminating findings: the dual pathology of autoimmune inflammation plus tau deposition requires addressing both components. Option D (combined immunotherapy with steroids, IVIG, and rituximab) is the keyed answer and aligns with published case series showing modest benefit from multimodal immunotherapy, though outcomes remain limited due to underlying tauopathy. Option A (high-dose methylprednisolone alone): monotherapy insufficient per literature. Option B (plasma exchange): limited efficacy as monotherapy in IgLON5 disease. Option C (rituximab alone): insufficient as monotherapy. Option E (trazodone): symptomatic sleep aid that cannot restore REM architecture or address underlying pathology. The stem provides sufficient detail to identify combined immunotherapy as the evidence-based approach. Medical accuracy: The characterization of IgLON5 disease as a tauopathy-mediated autoimmune disorder with modest response to combined immunotherapy is consistent with current literature. Minimal fix: None needed; item is logically valid and medically accurate.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes classic anti-IgLON5 disease: progressive insomnia, dysautonomia, bulbar dysfunction, gait instability, polysomnography showing REM sleep loss, and positive anti-IgLON5 antibodies. The question asks which therapeutic strategy has demonstrated modest symptomatic benefit. Key discriminating findings: the dual pathology of autoimmune inflammation plus tau deposition requires addressing both components. Option D (combined immunotherapy with steroids, IVIG, and rituximab) is the keyed answer and aligns with published case series showing modest benefit from multimodal immunotherapy, though outcomes remain limited due to underlying tauopathy. Option A (high-dose methylprednisolone alone): monotherapy insufficient per literature. Option B (plasma exchange): limited efficacy as monotherapy in IgLON5 disease. Option C (rituximab alone): insufficient as monotherapy. Option E (trazodone): symptomatic sleep aid that cannot restore REM architecture or address underlying pathology. The stem provides sufficient detail to identify combined immunotherapy as the evidence-based approach. Medical accuracy: The characterization of IgLON5 disease as a tauopathy-mediated autoimmune disorder with modest response to combined immunotherapy is consistent with current literature. Minimal fix: None needed; item is logically valid and medically accurate.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-008", "question": "A 28-year-old phenotypic female with 46,XY karyotype and complete androgen insensitivity syndrome (CAIS) due to a null androgen receptor mutation presents with hypertension (BP 165/100 mmHg) and hypokalemia (K+ 2.8 mEq/L). Plasma renin is suppressed (<0.5 ng/mL/hr) and aldosterone is elevated (35 ng/dL). Which pharmacologic agent specifically targets the underlying mineralocorticoid excess in this syndrome?", "options": ["Eplerenone 50 mg twice daily", "Spironolactone 100 mg twice daily", "Amiloride 10 mg twice daily", "Dexamethasone 0.5 mg nightly", "Finasteride 5 mg daily"], "answer": "B", "answer_index": 1, "explanation": "In CAIS, non-aromatized androgens directly activate mineralocorticoid receptors, causing hypertension. Spironolactone (B) antagonizes this effect while also blocking residual androgen receptor activity. Eplerenone (A) is less effective at the androgen-mediated mineralocorticoid effect. Amiloride (C) treats symptoms but not the mechanism. Dexamethasone (D) suppresses ACTH but not peripheral androgen production. Finasteride (E) blocks 5-alpha-reductase, irrelevant in CAIS with absent receptor function.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer is incorrect. The stem describes a patient with CAIS presenting with hypertension, hypokalemia, suppressed renin, and elevated aldosterone - classic findings of primary hyperaldosteronism or mineralocorticoid excess. The question asks which agent 'specifically targets the underlying mineralocorticoid excess.' Key stem clues: 46,XY CAIS with null AR mutation, hypertension, hypokalemia, suppressed renin, elevated aldosterone. The rationale claims non-aromatized androgens activate mineralocorticoid receptors in CAIS, but this is medically inaccurate. With a null AR mutation, there is NO functional androgen receptor, so androgens cannot exert effects through AR. The elevated aldosterone (35 ng/dL) indicates true aldosterone excess, not androgen-mediated MR activation. For aldosterone-driven MR activation, eplerenone (A) is the specific MR antagonist without anti-androgenic effects, making it the correct answer. Spironolactone (B) has anti-androgenic activity that is irrelevant in CAIS with absent AR function. The rationale's claim that spironolactone 'blocks residual androgen receptor activity' is nonsensical given the null mutation. Main medical issue: fundamental misunderstanding of CAIS pathophysiology and MR pharmacology. Minimal fix: Change key to A (eplerenone) or rewrite the clinical scenario to involve functional AR with androgen excess.\", \"medical_accuracy_score\": \"2\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer is incorrect. The stem describes a patient with CAIS presenting with hypertension, hypokalemia, suppressed renin, and elevated aldosterone - classic findings of primary hyperaldosteronism or mineralocorticoid excess. The question asks which agent 'specifically targets the underlying mineralocorticoid excess.' Key stem clues: 46,XY CAIS with null AR mutation, hypertension, hypokalemia, suppressed renin, elevated aldosterone. The rationale claims non-aromatized androgens activate mineralocorticoid receptors in CAIS, but this is medically inaccurate. With a null AR mutation, there is NO functional androgen receptor, so androgens cannot exert effects through AR. The elevated aldosterone (35 ng/dL) indicates true aldosterone excess, not androgen-mediated MR activation. For aldosterone-driven MR activation, eplerenone (A) is the specific MR antagonist without anti-androgenic effects, making it the correct answer. Spironolactone (B) has anti-androgenic activity that is irrelevant in CAIS with absent AR function. The rationale's claim that spironolactone 'blocks residual androgen receptor activity' is nonsensical given the null mutation. Main medical issue: fundamental misunderstanding of CAIS pathophysiology and MR pharmacology. Minimal fix: Change key to A (eplerenone) or rewrite the clinical scenario to involve functional AR with androgen excess.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-009", "question": "A 48-year-old woman with systemic sclerosis presents with NYHA class IV dyspnea. Right heart catheterization: mPAP 52 mmHg, PAWP 6 mmHg, PVR 11 WU. Lung biopsy shows diffuse capillary proliferation within alveolar septa without cellular atypia. She fails to respond to epoprostenol and macitentan. Which intervention is associated with the greatest 5-year survival in this rare WHO Group 1' pulmonary hypertension subset?", "options": ["Switch to inhaled treprostinil 54 μg four times daily", "Add selexipag 1600 μg twice daily", "Initiate combination immunosuppression with cyclophosphamide", "Refer for bilateral lung transplantation", "Perform balloon pulmonary angioplasty"], "answer": "D", "answer_index": 3, "explanation": "Pulmonary capillary hemangiomatosis (PCH) is refractory to all PAH-targeted therapies (A, B) and immunosuppression (C). Balloon angioplasty (E) is contraindicated due to diffuse microvascular disease. Bilateral lung transplantation (D) offers the only survival benefit, with 5-year survival approaching 60% in selected patients, far exceeding the <20% survival on medical therapy alone.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. The vignette describes pulmonary capillary hemangiomatosis (PCH), a rare WHO Group 1' pulmonary hypertension variant characterized by diffuse capillary proliferation within alveolar septa. Key discriminating findings include: (1) severe PAH (mPAP 52, PAWP 6, PVR 11 WU) in systemic sclerosis patient, (2) pathognomonic biopsy showing diffuse capillary proliferation without atypia, (3) failure of dual PAH-targeted therapy (epoprostenol + macitentan). PCH is notoriously refractory to all PAH medications and carries dismal prognosis on medical therapy alone. Option D (bilateral lung transplantation) is correct as it offers the only definitive treatment with 5-year survival ~50-60% versus <20% with medical management. Options A-B (alternative PAH therapies) are ineffective in PCH and may precipitate life-threatening pulmonary edema. Option C (immunosuppression) lacks evidence in PCH. Option E (balloon angioplasty) is contraindicated as it targets proximal CTEPH, not diffuse microvascular disease. The item is medically accurate, logically sound, and supports a unique best answer. No fix needed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. The vignette describes pulmonary capillary hemangiomatosis (PCH), a rare WHO Group 1' pulmonary hypertension variant characterized by diffuse capillary proliferation within alveolar septa. Key discriminating findings include: (1) severe PAH (mPAP 52, PAWP 6, PVR 11 WU) in systemic sclerosis patient, (2) pathognomonic biopsy showing diffuse capillary proliferation without atypia, (3) failure of dual PAH-targeted therapy (epoprostenol + macitentan). PCH is notoriously refractory to all PAH medications and carries dismal prognosis on medical therapy alone. Option D (bilateral lung transplantation) is correct as it offers the only definitive treatment with 5-year survival ~50-60% versus <20% with medical management. Options A-B (alternative PAH therapies) are ineffective in PCH and may precipitate life-threatening pulmonary edema. Option C (immunosuppression) lacks evidence in PCH. Option E (balloon angioplasty) is contraindicated as it targets proximal CTEPH, not diffuse microvascular disease. The item is medically accurate, logically sound, and supports a unique best answer. No fix needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-010", "question": "A 62-year-old man with chronic type B aortic dissection (diagnosed 3 years ago) presents with massive hemoptysis. CT angiography shows a 7 cm ulcer-like projection in the descending thoracic aorta with active contrast extravasation into the left lower lobe bronchus. He is hypotensive (BP 85/50 mmHg). Which immediate management strategy has the lowest mortality in this aortobronchial fistula complication?", "options": ["Emergent thoracotomy with open surgical repair", "Thoracic endovascular aortic repair (TEVAR) with left subclavian coverage", "TEVAR with adjunctive left subclavian artery revascularization", "Balloon tamponade of the aortic true lumen", "Massive transfusion protocol only"], "answer": "C", "answer_index": 2, "explanation": "Aortobronchial fistula requires emergent TEVAR to seal the rupture. Adjunctive left subclavian revascularization (C) prevents spinal ischemia and reduces perioperative stroke risk compared to coverage alone (B). Open repair (A) carries >80% mortality in this setting. Balloon tamponade (D) is a temporary bridge only. Transfusion alone (E) is futile without definitive hemorrhage control.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - option B is the correct best answer, not C. The stem describes a hypotensive patient with massive hemoptysis from an aortobronchial fistula with active extravasation requiring emergent intervention. Key discriminating findings: hemodynamic instability (BP 85/50), active contrast extravasation, and life-threatening hemorrhage. The clinical problem demands immediate hemorrhage control to prevent exsanguination. Option B (emergent TEVAR with left subclavian coverage) provides the fastest definitive control of bleeding. Option C adds left subclavian revascularization, which delays the life-saving intervention in a patient who is actively bleeding and hypotensive. While subclavian revascularization may reduce stroke/spinal ischemia risk in elective or stable settings, it is NOT the priority in a hypotensive patient with active extravasation who needs immediate hemorrhage control. The rationale incorrectly prioritizes complication prevention over immediate survival. In emergent aortobronchial fistula with hemodynamic instability, rapid TEVAR alone (B) has lower mortality than delayed TEVAR with revascularization (C). Options A, D, and E are appropriately eliminated. Minimal fix: Change the key to B, or modify the stem to indicate hemodynamic stability, allowing time for adjunctive revascularization.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - option B is the correct best answer, not C. The stem describes a hypotensive patient with massive hemoptysis from an aortobronchial fistula with active extravasation requiring emergent intervention. Key discriminating findings: hemodynamic instability (BP 85/50), active contrast extravasation, and life-threatening hemorrhage. The clinical problem demands immediate hemorrhage control to prevent exsanguination. Option B (emergent TEVAR with left subclavian coverage) provides the fastest definitive control of bleeding. Option C adds left subclavian revascularization, which delays the life-saving intervention in a patient who is actively bleeding and hypotensive. While subclavian revascularization may reduce stroke/spinal ischemia risk in elective or stable settings, it is NOT the priority in a hypotensive patient with active extravasation who needs immediate hemorrhage control. The rationale incorrectly prioritizes complication prevention over immediate survival. In emergent aortobronchial fistula with hemodynamic instability, rapid TEVAR alone (B) has lower mortality than delayed TEVAR with revascularization (C). Options A, D, and E are appropriately eliminated. Minimal fix: Change the key to B, or modify the stem to indicate hemodynamic stability, allowing time for adjunctive revascularization.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}]